ClinicalTrials.gg
RecruitingNCT07826546Updated Sep 17, 2026

Is Central Sensitization a Prognostic Indicator in Chronic Nonspecific Low Back Pain?

An observational study in Chronic Nonspecific Low Back Pain, sponsored by Mardin Artuklu University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Mardin Artuklu University · Observational

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
180
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 295 studies in Low Back Pain with a site in Turkey — 63 open to participants now, 73 under way, none of them phase 3. Low Back Pain · Turkey.

Planned enrollment
16th of 83
180 · median 107
Started
2026
with 37 others
Observational
83 of 295
20 open now
Primary completion
2027-06
later than 69 of 72 live
Registered
287th of 295
by date

Among the 295 studies in Low Back Pain with a site in Turkey, this one is the 16th largest by planned enrollment of the 83 observational ones that give a count, is one of 38 that started in 2026, is one of 83 observational ones, reaches primary completion later than 69 of the 72 other live ones, and was the 287th registered.

Low Back Pain

2,929 studies on the registry are indexed under Low Back Pain; 580 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

63 of the 295 studies in Low Back Pain with a site in Turkey are open now. Recruiting first, the newest first:

57 more — sign in →

All 63 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 295 studies in Low Back Pain with a site in Turkey, or all of them as a file.
02

Study summary

This observational study will examine whether signs of increased sensitivity in the nervous system at the beginning of the study are associated with short-term clinical outcomes in adults with chronic nonspecific low back pain. Approximately 180 participants will complete questionnaires about central sensitization, disability, pain, anxiety, and depression at the beginning of the study.

After 6 weeks, disability, pain, and the participant's overall perception of change will be assessed again. The researchers will evaluate whether the initial level of central sensitization is associated with meaningful improvement in disability and perceived treatment benefit. Participants will not be assigned to a treatment as part of this study and will continue to receive routine clinical care.

Read the detailed description

Background: Chronic nonspecific low back pain may have different clinical outcomes among patients. These differences cannot always be explained by structural findings. Central sensitization may be one of the factors related to treatment outcomes.

Objective: This study aims to investigate whether the baseline Central Sensitization Inventory (CSI) score can predict short-term clinical improvement and perceived treatment benefit in patients with chronic nonspecific low back pain.

Method: This prospective observational study will include 180 adults with chronic nonspecific low back pain. At baseline, the CSI, Oswestry Disability Index (ODI), Visual Analog Scale for pain, and Hospital Anxiety and Depression Scale will be completed. After 6 weeks of routine clinical care, the ODI, pain score, and Global Rating of Change will be evaluated again. A decrease of at least 30% in the ODI score will be accepted as clinically meaningful improvement. The relationship between the baseline CSI score and clinical outcomes at 6 weeks will be analyzed.

03

Conditions studied

  • Chronic Nonspecific Low Back Pain

Browse trials for

Keywords

  • Central Sensitization
  • Chronic Low Back Pain
  • Nonspecific Low Back Pain
  • Oswestry Disability Index
  • Prognostic Factor
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults aged 18-65 years with chronic nonspecific low back pain lasting for at least 3 months will be recruited from the Physical Medicine and Rehabilitation outpatient clinic of Mardin Training and Research Hospital. Participants will receive routine clinical care and will be evaluated at baseline and after 6 weeks. No healthy control group will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 65 years
  • Diagnosis of chronic nonspecific low back pain lasting for at least 3 months
  • Willingness to participate in the study
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • Progressive neurological deficit
  • Inflammatory rheumatic disease
  • Active
  • History of serious spinal trauma or spinal surgery
  • Cognitive impairment that may prevent completion of the assessments or follow-up
  • Initiation, dose modification, or change of antidepressant or gabapentinoid treatment within the previous 3 months
  • Pregnancy, postpartum period, or breastfeeding
  • Inability to provide
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
180 participants (estimated)
Patient registry
No

Groups and cohorts

  • Chronic Nonspecific Low Back Pain Cohort

    Adults aged 18-65 years with chronic nonspecific low back pain will be evaluated at baseline and followed for 6 weeks. Participants will receive routine clinical care determined by their treating physician. No treatment or intervention will be assigned by the study protocol. Baseline central sensitization symptoms will be evaluated in relation to disability, pain, and perceived improvement at 6 weeks.

06

What researchers measure

Primary outcomes

  1. Clinically Meaningful Improvement in the Oswestry Disability Index

    The proportion of participants who achieve a reduction of at least 30% in the Oswestry Disability Index (ODI) score from baseline. The ODI ranges from 0 to 100, with higher scores indicating greater disability.

    Time frame: Baseline to 6 weeks

Secondary outcomes

  1. Change in the Oswestry Disability Index Score

    Change in the Oswestry Disability Index (ODI) score from baseline to 6 weeks. The ODI ranges from 0 to 100, with higher scores indicating greater disability. A greater reduction indicates greater improvement in disability.

    Time frame: Baseline to 6 weeks

  2. Change in Pain Intensity

    Change in pain intensity measured using a 0-10 Visual Analog Scale from baseline to 6 weeks. A score of 0 indicates no pain, and a score of 10 indicates the worst possible pain. A greater reduction indicates greater improvement in pain.

    Time frame: Baseline to 6 weeks

  3. Patient-Perceived Improvement

    Patient-perceived change in overall clinical status will be assessed using the Global Rating of Change scale at 6 weeks. Participants will report whether their condition has improved, remained unchanged, or worsened compared with baseline. The responses will be classified as perceived treatment benefit or no perceived treatment benefit according to the prespecified study criteria.

    Time frame: At 6 weeks

07

Study locations

1 of 1 sites recruiting
  • Mardin Training and Research Hospital
    Mardin, 47100, Turkey (Türkiye)
    Recruiting
    • Taha Yasin YILDIRIM, M.D. · Contacttyasinyildirim.ftr@gmail.com · +90 534 220 77 17
    • Taha Yasin YILDIRIM, M.D. · Sub investigator
    • Hatice Gözde Sümer, M.D. · Principal investigator
08

References and documents

Publications

  • Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011 Mar;152(3 Suppl):S2-S15. doi: 10.1016/j.pain.2010.09.030. Epub 2010 Oct 18. PubMed 20961685 ↗
  • Nijs J, George SZ, Clauw DJ, Fernandez-de-Las-Penas C, Kosek E, Ickmans K, Fernandez-Carnero J, Polli A, Kapreli E, Huysmans E, Cuesta-Vargas AI, Mani R, Lundberg M, Leysen L, Rice D, Sterling M, Curatolo M. Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine. Lancet Rheumatol. 2021 May;3(5):e383-e392. doi: 10.1016/S2665-9913(21)00032-1. Epub 2021 Mar 30. PubMed 38279393 ↗
  • Sheenam N, Gaur R, Gonnade NM, Abins TK, Ghosh A, Hussain R. Central sensitisation in chronic low back pain: A cross-sectional study. Indian J Anaesth. 2025 Oct;69(10):1033-1038. doi: 10.4103/ija.ija_433_25. Epub 2025 Sep 5. PubMed 40979767 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.

Of 177 non-industry observational studies under Low Back Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's planned 12 months is below that.

Counting every sponsor, half of 187 studies reached it within 24 months; a quarter within 10 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2026
First posted
Sep 17, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07826546
Lead sponsor
Mardin Artuklu University
Collaborators
Mardin Training and Research Hospital
Responsible party
Hatice Gözde Sümer (M.D., Mardin Artuklu University) — Principal investigator
First posted
Sep 17, 2026
Start date
Jun 1, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

Taha Yasin YILDIRIM, M.D.
Contact
tyasinyildirim.ftr@gmail.com
+90 534 220 77 17
Hatice Gözde Sümer, M.D.
Contact
gzdsmr@outlook.com
+90 532 157 72 99

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion